The clinical value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in postoperative patients with gastrointestinal mucinous adenocarcinoma

Nuclear Medicine Communications

Volumn 32, Issue 11, 2011, Pages 1018-1025

  Yang, Zhong Yi ^a,b   Hu, Si Long ^a,b   Shi, Wei ^a,b   Zhu, Bei Ling ^a,b   Xu, Jun Yan ^a,b   Zhang, Ying Jian ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

18F fluorodeoxyglucose; follow up; gastrointestinal cancer; mucinous adenocarcinoma; positron emission tomography computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; DRUG UPTAKE; EVALUATION; FEMALE; FOLLOW UP; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL MUCINOUS ADENOCARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LYMPH NODE METASTASIS; MALE; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIMARY TUMOR; RECTUM CANCER; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; SURGICAL PATIENT;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PERITONEUM; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80053549350     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834bbd22     Document Type: Article

References (33)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-2150. (Pubitemid 46655601)
2. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009; 374:477-490.
3. Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, et al. Asia-Pacific Gastric Cancer Consensus Conference. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23:351-365. (Pubitemid 351342074)
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59:225-249.
5. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 2004; 22:2767-2773. (Pubitemid 41079893)
6. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006; 244:254-259. (Pubitemid 44305540)
7. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231:305-332. (Pubitemid 38552885)
8. Laurent V, Olivier P. Imaging and PET/CT evaluation of GI tract cancers. J Radiol 2008; 89:413-435.
9. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. Am J Roentgenol 2000; 174:1005-1008. (Pubitemid 30179992)
10. Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med 2006; 20:597-604. (Pubitemid 44954052)
11. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006; 9:192-196. (Pubitemid 44426892)
12. Cook GJR, Fogelman I, Maisey M. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 26:308-314. (Pubitemid 126789027)
13. Heusner TA, Hahn S, Hamami ME, Kim UH, Baumeister R, Forsting M, et al. Gastrointestinal 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development. Eur Radiol 2009; 19:2171-2179.
14. Salaun PY, Grewal RK, Dodamane I, Yeung HW, Larson SM, Strauss HW. An analysis of the 18F-FDG uptake pattern in the stomach. J Nucl Med 2005; 46:48-51. (Pubitemid 43085997)
15. Josephs D, Spicer J, ODoherty M. Molecular imaging in clinical trials. Target Oncol 2009; 4:151-168.
16. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology 2007; 244:39-47. (Pubitemid 46981957)
17. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med 2006; 57:99-118. (Pubitemid 43261981)
18. Jager PL, de Korte MA, Lub-de Hooge MN, van Waarde A, Koopmans KP, Perik PJ, et al. Molecular imaging: what can be used today. Cancer Imaging 2005; 5 (Spec. No. A):S27-S32.
19. Abhyankar SA, Nair N. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate. Clin Nucl Med 2008; 33:213-214. (Pubitemid 351301561)
20. Scott AM, Gunawardana DH, Kelley B, Stuckey JG, Byrne AJ, Ramshaw JE, et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med 2008; 49:1451-1457.
21. Tan MC, Castaldo ET, Gao F, Chari RS, Linehan DC, Wright JK, et al. A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables. J Am Coll Surg 2008; 206:857-868.
22. Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008; 98:875-880. (Pubitemid 351341613)
23. Sun L, Su XH, Guan YS, Pan WM, Luo ZM, Wei JH, et al. Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results. World J Gastroenterol 2008; 14:4627-4632.
24. Sim SH, Kim YJ, Oh DY, Lee SH, Kim DW, Kang WJ, et al. The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer 2009; 9:73.
25. Sarikaya I, Bloomston M, Povoski SP, Zhang J, Hall NC, Knopp MV, et al. FDGPET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 2007; 5:64.
26. Takanami K, Hiraide T, Kaneta T, Hayashi H, Unno M, Fujishima F, et al. FDG PET/CT findings in malignant intraductal papillary mucinous neoplasm of the bile ducts. Clin Nucl Med 2010; 35:83-85.
27. Fukui MB, Blodgett TM, Snyderman CH, Johnson JJ, Myers EN, Townsend DW, et al. Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics 2005; 25:913-930. (Pubitemid 41196929)
28. Lerut T, Flamen P, Ectors N, Van Cutsem E, Peeters M, Hiele M, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000; 232:743-752.
29. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 2003; 44:690-699. (Pubitemid 39655202)
30. Lim JS, Kim MJ, Yun MJ, Oh YT, Kim JH, Hwang HS, et al. Comparison of CT and 18F-FDG PET for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma. Korean J Radiol 2006; 7:249-256. (Pubitemid 44905083)
31. Squillaci E, Manenti G, Mancino S, Cicciò C, Calabria F, Danieli R, et al. Staging of colon cancer: whole-body MRI versus whole-body PET-CT-initial clinical experience. Abdom Imaging 2008; 33:676-688.
32. De Wever W, Meylaerts L, De Ceuninck L, Stroobants S, Verschakelen JA. Additional value of integrated PET-CT in the detection and characterization of pulmonary metastases: correlation with CT alone and PET alone. Eur Radiol 2007; 17:467-473. (Pubitemid 46140317)
33. Chen W, Parsons M, Torigian DA, Zhuang H, Alavi A. Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun 2009; 30:240-244.